17只个股今日获机构买入型评级，9股机构首次关注。 证券时报·数据宝统计显示，今日机构研报共发布18条买入型评级记录，共涉及17只个股。天山铝业关 注度最高，共获2次机构买入型评级记录。 今日获机构买入型评级个股中，共有6条评级记录中对相关个股给出了未来目标价。以公布的预测目标 价与最新收盘价进行对比显示，共有6股上涨空间超10%，创业环保上涨空间最高，6月10日广发证券预 计公司目标价为7.24元，上涨空间达23.13%，上涨空间较高的个股还有电投能源、天山铝业等，上涨空 间分别为20.91%、16.71%。 行业来看，环保、机械设备等行业最受青睐，均有2只个股上榜机构买入评级榜。基础化工、医药生物 等行业也较受机构关注，分别有2只、2只个股上榜。（数据宝） 机构今日买入型评级记录 | 代码 | 简称 | 机构名称 | 最新评级 | 上次评级 | 预测目标价（元） | 最新收盘价（元） | | --- | --- | --- | --- | --- | --- | --- | | 002128 | 电投能源 | 广发证券 | 买入 | 未评级 | 24.11 | 19.94 | | 301078 | 孩子王 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has received approval for its self-developed innovative traditional Chinese medicine, "Yangxue Qufeng Zhitong Granules," which is expected to enhance the performance of its cardiovascular segment [4] - The market potential for the new product is promising, particularly in addressing the high prevalence of tension-type headaches, which account for a significant portion of primary headache cases [5][6] - The company maintains its profit forecasts for 2025-2027, projecting net profits of 308 million, 378 million, and 457 million yuan respectively, with corresponding EPS of 0.70, 0.86, and 1.04 yuan [4] Financial Summary - Revenue is projected to grow from 1,629 million yuan in 2023 to 2,617 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 13.9% [8] - The gross margin is expected to remain stable, with estimates of 71.6% in 2025 and gradually increasing to 72.6% by 2027 [8] - The company's P/E ratio is projected to decrease from 25.7 in 2023 to 10.5 in 2027, indicating an improving valuation over time [8]

Domestic Financial Market - In May, the national consumer price index (CPI) decreased by 0.1% year-on-year, while the producer price index (PPI) fell by 3.3% year-on-year [4] - In May, China's total goods trade import and export value reached 3.81 trillion yuan, an increase of 2.7%, with exports growing by 6.3% and imports declining by 2.1% [4] Industry Dynamics - The upcoming Volcano Engine Power Conference is expected to benefit the AI industry chain, with related stocks including Hand Information (300170) and Runxin Technology (300493) [5] - During the "618" shopping festival, beauty products became the main sales force on e-commerce platforms, with related stocks such as Marubi Biotechnology (603983) and Proya Cosmetics (603605) [5] - The satellite internet industry is accelerating its progress, with institutions indicating potential for valuation expansion, related stocks include Shanghai Huguang (603131) and Parker New Materials (605123) [5] Company Focus - Longshen Rongfa (300534) received CNAS laboratory accreditation for its controlling subsidiary, which is expected to positively impact future operations [6] - Fangsheng Pharmaceutical (603998) obtained a drug registration certificate for its innovative traditional Chinese medicine product [6] - Fuda Alloy (603045) saw its controlling shareholder increase holdings by 7,700 shares [6] - Maixinlin (688685) signed a 1.184 billion yuan computing power service contract, which is expected to positively affect the company's performance in 2025 and beyond [6] Market Review and Outlook - On June 9, the market opened slightly higher and continued to rise, with the Shanghai Composite Index closing at 3,399 points, up 0.43%, and the ChiNext Index rising over 1% [7] - The market showed broad gains with over 4,200 stocks rising, while sectors like chemical pharmaceuticals, aerospace equipment, and cultural media performed well [7] - The market is expected to break out of its current range if incremental capital continues to flow in, with a focus on holding positions and seeking low-level opportunities [8]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-061 湖南方盛制药股份有限公司 关于中药创新药养血祛风止痛颗粒获得 《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025年6月9日，湖南方盛制药股份有限公司（以下简称"公 司"）全资子公司广东方盛健盟药业有限公司（以下简称"健盟 药业"）收到国家药品监督管理局（以下简称"国家药监局"） 核准签发的《药品注册证书》，公司自主研发的中药创新药养血 祛风止痛颗粒已获得药品批准文号，并可进行生产。2024年9月 18日，公司已就该药品的注册进展情况发布了提示性公告（具体 内容详见公司2024-076号公告）。现将相关情况公告如下： 二、药品研究情况 养血祛风止痛颗粒基于中国近代著名中医大家张锡纯先生 第 1 页，共 5 页 药品名称 养血祛风止痛颗粒 受理号 CXZS2400030 证书编号 2025S01680 主要成分 黄芪、当归、党 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [7] Core Insights - The report highlights that the Chinese innovative drug sector is poised to capitalize on the patent cliff faced by multinational corporations (MNCs), with a potential market space exceeding $240 billion due to the expiration of patents on 31 major drugs by 2037 [5][18] - It emphasizes that China has the largest number of innovative drug pipelines globally, particularly in cell therapy, ADCs, and bispecific antibodies, which positions it as a key player in the global market [5][32] - The report suggests that the ongoing trend of licensing out Chinese innovations to MNCs could lead to significant profit opportunities, estimating a net profit of approximately $8.2 billion from authorized projects between 2020 and 2025, translating to a potential market capitalization increase of $81.7 billion [5][46][47] Summary by Sections Market Review - The report notes that the CITIC Pharmaceutical Index rose by 1.2% during the week of June 3-6, 2025, outperforming the CSI 300 Index by 0.3 percentage points [4][48] - The pharmaceutical sector has shown a year-to-date increase of 8.3%, surpassing the CSI 300 Index by 9.9 percentage points [4][48] MNC Patent Cliff - The report identifies that 27 drugs with projected sales exceeding $4 billion in 2024 will face patent expiration by 2037, leading to a potential loss of approximately $244.3 billion for MNCs [18][19] - Specific drugs mentioned include Merck's Keytruda and Pfizer's Eliquis, which are expected to face significant sales declines post-patent expiration [19][20] Supply and Demand Dynamics - China leads globally in the number of innovative drug pipelines, particularly in cell therapy and ADCs, with 58% of these drugs currently in clinical phase I trials [32][33] - The report indicates that Chinese companies are involved in 716 research tracks, ranking first in development progress [32][33] Transaction Trends - The report highlights a significant increase in global pharmaceutical transactions, with the number of deals rising from 358 in 2015 to 743 in 2024, and total transaction value increasing from $56.9 billion to $187.4 billion [36][39] - Chinese companies accounted for 30% of global transaction value in 2024, with a total of $57.1 billion in deals [39][40] Investment Recommendations - The report suggests focusing on companies with strong overseas clinical progress and those with potential for significant licensing deals, including Innovent Biologics, Eddingpharm, and others [5][6] - It also recommends monitoring companies that have received approval for commercialization, such as BeiGene and Kingsoft Biopharma [5][6]

Core Insights - The opening of Yonghui Supermarket's Jiading Baolong store marks the sixth location in Shanghai adopting the "Pang Donglai" model, resulting in a significant increase in customer traffic and sales [1][5][35] - The store experienced a 318% year-on-year increase in customer flow and a 716% increase in sales during the first three days of operation [5][34] - The transformation of traditional supermarkets in Shanghai, such as the Century Lianhua Luban store, has also led to a resurgence in customer interest, indicating a broader trend in the retail sector [34][40] Group 1 - Yonghui's Jiading Baolong store has implemented a product structure that aligns with the "Pang Donglai" model, reducing the number of standard products from over 10,000 to around 8,000, with over 80% of the product structure now reflecting the "Pang Donglai" model [14][35] - The store introduced 67 self-owned brand products from "Pang Donglai," with a total of 8,868 items available after restructuring [11][14] - The bakery and ready-to-eat food sections have become particularly popular, with significant customer engagement observed in these areas [17][31] Group 2 - The store has adopted a limit purchase policy for certain "Pang Donglai" products, requiring customers to show an electronic membership code from the Yonghui app to make purchases [11][13] - The service quality at the Jiading store has been noted as a strong point, with various customer-friendly features implemented, although some staff members are still in training [24][28] - The store's layout has been optimized to enhance customer flow, separating high-traffic areas like the bakery and ready-to-eat food sections to improve shopping experience [14][31] Group 3 - The success of Yonghui's transformation is part of a larger trend in Shanghai's retail landscape, with other stores like Century Lianhua also reporting increased customer traffic following similar renovations [34][40] - The focus on community engagement and tailored services, such as the "潮银俱乐部" (潮银 Club) for the elderly, reflects a strategic shift towards meeting specific consumer needs [40][42] - The overall strategy involves reducing the number of low-efficiency, homogeneous products while enhancing the quality and variety of offerings, aiming to create a more engaging shopping experience [34][40]

Group 1 - The company Hunan Fangsheng Pharmaceutical Co., Ltd. has acquired the ownership of 20 registered drug varieties from Kangyi Pharmaceutical Co., Ltd. in Hong Kong [1] - A joint venture company in Hong Kong is to be established with a registered capital of 20 million HKD, where the company will hold 35% initially [1] - The company plans to sign a new drug transfer agreement with Kangyi Pharmaceutical after the establishment of the joint venture [1] Group 2 - Due to regulatory issues regarding foreign investment, the company has adjusted its shareholding structure in the joint venture, increasing its stake from 35% to 50% and raising its investment from 7 million HKD to 10 million HKD [2] - The new shareholding structure includes other parties with varying stakes, ensuring compliance with investment regulations [2][3] - The joint venture will officially sign the investment cooperation agreement to clarify the rights and obligations of all parties involved [3] Group 3 - The adjustment in the shareholding structure of the joint venture is not expected to significantly impact the company's normal operations or financial results [3] - The transfer of drug licenses is still in process and is not affected by the changes in the joint venture [3]

Group 1 - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased over 70 original research results from China, highlighting the increasing recognition of Chinese innovative drugs in the capital market [1] - Chinese innovative drug companies are entering a profitable phase, with significant business development (BD) transactions contributing to substantial profit returns, leading to a systematic increase in valuations for innovative drugs [1][2] - The number of original innovative drugs developed by Chinese companies has surged from 124 in 2015 to 704 in 2024, positioning China as a global leader in original drug research and development [1] Group 2 - From 2015 to 2024, the number and value of outbound licensing transactions by Chinese pharmaceutical companies have consistently increased, reaching a peak of $51.9 billion in total transaction value in 2024 [2] - Notable transactions include the $6.05 billion deal between 3SBio and Pfizer for the PD-1/VEGF dual antibody drug, setting a record for Chinese innovative drugs entering international markets [2] - The leading position of Chinese companies in new technologies such as bispecific antibodies and antibody-drug conjugates is expected to drive further significant BD transactions in the coming years [2] Group 3 - The recognition of domestic innovative drugs and the influx of large BD deals have heightened investor interest in companies operating in the innovative drug sector [3] - Companies like Hunan Warner Pharmaceutical and Hunan Fosheng Pharmaceutical are actively advancing their innovative drug projects, with several candidates in various stages of clinical trials [3] - Multiple listed companies have reported progress in the innovative drug field, with a significant number of products entering clinical stages, including 24 key products from Changchun High-tech and ongoing trials for new drugs from Hainan Haiyao [3] Group 4 - The innovative drug industry is currently experiencing a dual wave of technological breakthroughs and global expansion, with leading companies expected to drive industry transformation [4] - The development of innovative drugs requires substantial technical accumulation and financial backing, emphasizing the need for professional research and careful selection of quality innovative drug companies for investment [4]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 关于受让药品上市许可的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 2025 年 3 月 25 日，湖南方盛制药股份有限公司（以下简称 "方盛制药"或"公司"）受让康溢医药有限公司（以下简称"康 溢医药"）持有的"喉咽清胶囊""浙贝止咳露（黄盒）"等合 计 20 个在香港特别行政区卫生署（以下简称"香港卫生署"） 注册的药品品种的所有权；并于同日与港捷有限公司（以下简称 "港捷公司"）、自然人赵国灏先生及向红梅女士签订《投资合 作协议》，拟在香港特别行政区成立合资子公司（以下简称"香 港合资公司"），注册资本 2,000 万港元，公司以自有资金出资 700 万港元，持股 35%，为公司控股子公司；该合资子公司成立 后，其将按照《投资合作协议》《药品品种转让协议》的相关约 定，与康溢医药就上述 20 个药品品种转让重新签订《药品品种 转让协议》并履行相关义务（详见公司 20 ...

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. plans to increase capital in its subsidiary Fangsheng R&D Co. with a total investment of 24 million yuan from the company and its partners, aiming to enhance its drug research and development capabilities in the Guangdong-Hong Kong-Macao Greater Bay Area [2][3][12] Summary by Sections 1. Transaction Overview - Fangsheng Pharmaceutical intends to invest 24 million yuan in Fangsheng R&D Co., with New Yuan Investment contributing 46 million yuan, and both Tongmu Technology and the core talent holding entity contributing 5 million yuan each. Post-investment, the shareholding structure will be Fangsheng Pharmaceutical 35%, New Yuan Investment 55%, Tongmu Technology 5%, and the core talent holding entity 5% [2][3] - The investment is classified as a related party transaction due to the involvement of New Yuan Investment, which is an affiliated entity. Related directors abstained from voting [2][3] - The investment does not constitute a major asset restructuring as per regulations, and it has been approved by the independent directors and the board of directors without needing shareholder approval [2][4] 2. Purpose and Reason for the Capital Increase - The capital increase aims to support the company's strategic development in the Guangdong-Hong Kong-Macao Greater Bay Area, leveraging local resources and policies to accelerate the R&D of traditional Chinese medicine projects and mitigate R&D risks [3][12] 3. Related Party Information - New Yuan Investment is controlled by the same individual as Fangsheng Pharmaceutical, establishing a related party relationship. The core talent holding entity will consist of key personnel from the company, which may include current directors and senior management [6][7] 4. Capital Increase Details - The registered capital of Fangsheng R&D Co. will increase from 20 million yuan to 100 million yuan, with the new capital structure reflecting the contributions from all parties involved [9][10] - The governance structure will include a board of directors with three members, where Fangsheng Pharmaceutical appoints two directors and the chairman [10][12] 5. Impact on the Company - Following the capital increase, Fangsheng R&D Co. will remain under the control of Fangsheng Pharmaceutical, allowing it to consolidate its financial statements. This move is expected to enhance the sustainability of R&D investments and facilitate the commercialization of innovative traditional Chinese medicine [12]